Lamond David
Known title: DirectorCIK: 0001770790
Lamond David's purchase track record
How the stock did after each of Lamond David's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since August 15, 2023
Stock higher 6 months later
25%
3 months: 50%
Median 6-month return
-7.4%
3 months: -5.6%
Beat the S&P 500
0%
median -21.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/7/2023 | QNCX | $89K | +16.0% | -16.0% | +16.7% |
| 11/29/2023 | QNCX | $79K | +42.5% | -8.5% | +15.7% |
| 8/30/2023 | QNCX | $108K | -27.1% | +3.9% | +12.3% |
| 8/15/2023 | QNCX | $326K | -29.4% | -6.3% | +11.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| QNCX | ▲ Buy | Open Market | 22,627 | $24K | 12/14/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 22,627 | $23K | 12/13/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 300 | $300 | 12/12/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 22,327 | $23K | 12/12/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 19,123 | $19K | 12/7/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 19,123 | $20K | 12/6/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 19,123 | $19K | 12/5/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 14,378 | $14K | 12/1/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 14,378 | $13K | 11/30/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 14,378 | $14K | 11/29/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 41,026 | $54K | 8/31/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 41,026 | $54K | 8/30/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 24,766 | $32K | 8/17/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 117,348 | $151K | 8/16/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 107,886 | $142K | 8/15/2023 | View on chart |
| QNCX | ▲ Buy | Grant | 200,002 | — | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Quince Therapeutics LAM-001 Progress; Analyst Targets $70
Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.
Quince Therapeutics LAM-001 Progress; Analyst Targets $70. Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.